Tracking the real-world effects of Piqray in Korea
Part of Cancer, Skin clinical trials.
This study monitors how well and how safely Piqray works for people in Korea in routine care. You may be invited if your breast cancer matches specific genetic and receptor test results and you are starting Piqray for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or spread breast cancer that is hormone-receptor positive, HER2-negative, and has a PIK3CA mutation
- You have already tried hormone-based (endocrine) treatment, and now you will start Piqray for the first time
- You are able and willing to sign written consent
- You do not have a medical allergy or other reason you cannot take Piqray under Korea’s approved instructions
- If you can become pregnant, you must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world safety data for patients in South Korea who are taking Capivasertib as prescribed by their doctor according to the approved label. It helps ensure the drug continues to be safe and effective for people who need it.
This study follows breast cancer patients who are scheduled to receive radiotherapy at a National Cancer Center in Korea. By collecting information during and after treatment, researchers hope to better understand how patients do over time.
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
This trial tests a new pill (JYP0035) combined with fulvestrant, a standard hormone therapy, for advanced breast cancer that has a specific gene change called PIK3CA. The goal is to see if the combination helps control the cancer better than fulvestrant alone.
This study uses special PET/MRI scans to see how well breast cancer treatments are working. It aims to find better ways to monitor your cancer and guide your care.
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.